Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Biogen Inc Cmn (BIIB) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 62,073,860
  • Shares Outstanding, K 219,120
  • Annual Sales, $ 10,764 M
  • Annual Income, $ 3,547 M
  • 36-Month Beta 0.75
  • Price/Sales 5.85
  • Price/Book 5.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
278.58 +3.30%
on 12/08/16
329.83 -12.75%
on 11/10/16
-32.09 (-10.03%)
since 11/09/16
3-Month
268.00 +7.38%
on 11/04/16
329.83 -12.75%
on 11/10/16
-8.33 (-2.81%)
since 09/09/16
52-Week
223.02 +29.03%
on 06/27/16
333.65 -13.75%
on 08/02/16
+3.16 (+1.11%)
since 12/09/15

Most Recent Stories

More News
Stock Market News for December 09, 2016

Markets finished at record highs again on Thursday following ECB's announcement about trimming bond-buying volume and the continuing Trump induced rally.

Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis

Approval Supported by Largest and Longest Head-to-Head Global Phase 3 Study Conducted in Multiple Sclerosis (MS)

Biogen Presents Data from Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer's Disease Meeting

Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer's disease (AD), today at the...

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 8, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) concerning possible...

Investor Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016

NEW YORK / ACCESSWIRE / December 8, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB)...

Stock Market News for December 08, 2016

The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 5, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) concerning possible...

Shareholder Alert - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016

NEW YORK / ACCESSWIRE / December 5, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB)...

Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE(R) and ALPROLIX(R) Highlighted at 58th ASH Meeting

Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) will present new data, including updated longitudinal safety and efficacy findings from phase 3 ...

GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?

GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 317.37
1st Resistance Point 302.57
Last Price 287.77
1st Support Level 277.38
2nd Support Level 266.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.